The biotech beat Wall Street estimates. But there's still a big unanswered question.
News & Analysis: Nektar Therapeutics
NKTR earnings call for the period ending September 30, 2019.
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
An analyst downgrade is only adding to the company's woes.
Manufacturing issues plague the start-up.
The biotech continues to feel the repercussions from news announced last week.
Find out why these stocks stood out on a down day for the markets.
The biotech's manufacturing problems with a key experimental drug and uncertainty about a major partnership are rattling investors.
The biotech's Q2 numbers weren't nearly as sweet as they were a year ago. But the main focus continues to be on its pipeline progress.
NKTR earnings call for the period ending June 30, 2019.